vs
Side-by-side financial comparison of Arcellx, Inc. (ACLX) and REGENXBIO Inc. (RGNX). Click either name above to swap in a different company.
REGENXBIO Inc. is the larger business by last-quarter revenue ($30.3M vs $8.1M, roughly 3.7× Arcellx, Inc.). REGENXBIO Inc. runs the higher net margin — -221.3% vs -766.0%, a 544.7% gap on every dollar of revenue. On growth, REGENXBIO Inc. posted the faster year-over-year revenue change (43.0% vs -79.3%). REGENXBIO Inc. produced more free cash flow last quarter ($-52.8M vs $-63.9M). Over the past eight quarters, REGENXBIO Inc.'s revenue compounded faster (39.4% CAGR vs -24.6%).
Arcellx, Inc. is a clinical-stage biotechnology company that develops innovative chimeric antigen receptor T (CAR-T) cell therapies for treating hard-to-treat cancers including hematologic malignancies and solid tumors. Its core pipeline targets unmet oncology medical needs, serving global patient populations and partnering with life sciences stakeholders.
REGENXBIO Inc. is a clinical-stage biotechnology firm focused on gene therapy for rare severe genetic diseases. It licenses its proprietary AAV vector technology to global biopharma partners, and advances its own pipeline targeting ophthalmology, metabolic and neurodegenerative disorders.
ACLX vs RGNX — Head-to-Head
Income Statement — Q1 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.1M | $30.3M |
| Net Profit | $-62.3M | $-67.1M |
| Gross Margin | — | — |
| Operating Margin | -847.6% | -190.0% |
| Net Margin | -766.0% | -221.3% |
| Revenue YoY | -79.3% | 43.0% |
| Net Profit YoY | -765.1% | -31.2% |
| EPS (diluted) | $-1.13 | $-1.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $30.3M | ||
| Q3 25 | — | $29.7M | ||
| Q2 25 | — | $21.4M | ||
| Q1 25 | $8.1M | $89.0M | ||
| Q4 24 | $15.3M | $21.2M | ||
| Q3 24 | $26.0M | $24.2M | ||
| Q2 24 | $27.4M | $22.3M | ||
| Q1 24 | $39.3M | $15.6M |
| Q4 25 | — | $-67.1M | ||
| Q3 25 | — | $-61.9M | ||
| Q2 25 | — | $-70.9M | ||
| Q1 25 | $-62.3M | $6.1M | ||
| Q4 24 | $-47.1M | $-51.2M | ||
| Q3 24 | $-25.9M | $-59.6M | ||
| Q2 24 | $-27.2M | $-53.0M | ||
| Q1 24 | $-7.2M | $-63.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
| Q4 25 | — | -190.0% | ||
| Q3 25 | — | -176.3% | ||
| Q2 25 | — | -296.3% | ||
| Q1 25 | -847.6% | 13.6% | ||
| Q4 24 | -348.2% | -242.1% | ||
| Q3 24 | -129.1% | -256.6% | ||
| Q2 24 | -127.8% | -251.3% | ||
| Q1 24 | -40.3% | -408.8% |
| Q4 25 | — | -221.3% | ||
| Q3 25 | — | -208.3% | ||
| Q2 25 | — | -331.8% | ||
| Q1 25 | -766.0% | 6.8% | ||
| Q4 24 | -308.4% | -241.3% | ||
| Q3 24 | -99.4% | -246.3% | ||
| Q2 24 | -99.3% | -237.7% | ||
| Q1 24 | -18.3% | -405.4% |
| Q4 25 | — | $-1.30 | ||
| Q3 25 | — | $-1.20 | ||
| Q2 25 | — | $-1.38 | ||
| Q1 25 | $-1.13 | $0.12 | ||
| Q4 24 | $-0.87 | $-0.99 | ||
| Q3 24 | $-0.48 | $-1.17 | ||
| Q2 24 | $-0.51 | $-1.05 | ||
| Q1 24 | $-0.14 | $-1.38 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $543.3M | $230.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $416.9M | $102.7M |
| Total Assets | $648.1M | $453.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | $543.3M | $267.9M | ||
| Q4 24 | $587.4M | $234.7M | ||
| Q3 24 | $574.3M | $255.5M | ||
| Q2 24 | $516.7M | $290.4M | ||
| Q1 24 | $573.9M | $338.7M |
| Q4 25 | — | $102.7M | ||
| Q3 25 | — | $161.5M | ||
| Q2 25 | — | $213.7M | ||
| Q1 25 | $416.9M | $274.2M | ||
| Q4 24 | $454.8M | $259.7M | ||
| Q3 24 | $483.0M | $301.4M | ||
| Q2 24 | $487.2M | $348.3M | ||
| Q1 24 | $496.6M | $390.7M |
| Q4 25 | — | $453.0M | ||
| Q3 25 | — | $525.2M | ||
| Q2 25 | — | $581.0M | ||
| Q1 25 | $648.1M | $490.9M | ||
| Q4 24 | $711.3M | $466.0M | ||
| Q3 24 | $764.9M | $519.1M | ||
| Q2 24 | $734.3M | $569.4M | ||
| Q1 24 | $779.7M | $629.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-63.1M | $-52.3M |
| Free Cash FlowOCF − Capex | $-63.9M | $-52.8M |
| FCF MarginFCF / Revenue | -786.4% | -174.0% |
| Capex IntensityCapex / Revenue | 9.6% | 1.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-122.5M | $-126.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-52.3M | ||
| Q3 25 | — | $-56.0M | ||
| Q2 25 | — | $-49.3M | ||
| Q1 25 | $-63.1M | $33.6M | ||
| Q4 24 | $-46.0M | $-31.6M | ||
| Q3 24 | $30.7M | $-40.5M | ||
| Q2 24 | $-36.2M | $-45.5M | ||
| Q1 24 | $-31.9M | $-55.5M |
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | $-63.9M | $32.6M | ||
| Q4 24 | $-47.5M | $-32.7M | ||
| Q3 24 | $28.4M | $-40.9M | ||
| Q2 24 | $-39.5M | $-46.0M | ||
| Q1 24 | $-38.3M | $-56.0M |
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | -786.4% | 36.6% | ||
| Q4 24 | -311.3% | -154.2% | ||
| Q3 24 | 109.2% | -168.9% | ||
| Q2 24 | -144.1% | -206.2% | ||
| Q1 24 | -97.7% | -358.5% |
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | 9.6% | 1.2% | ||
| Q4 24 | 9.8% | 5.1% | ||
| Q3 24 | 8.8% | 1.3% | ||
| Q2 24 | 11.7% | 2.1% | ||
| Q1 24 | 16.4% | 3.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACLX
Segment breakdown not available.
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
